ArticleInvestigational new drugs2012

The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.

Francesco Carinci et al.PubMed ↗Publisher ↗

No numbers read from the abstract.